Onset of force development as a marker of thrombin generation
US7202048B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 3, 2003 |
| Grant date | Apr 10, 2007 |
| Priority date | — |
| Expiry date | Dec 28, 2024 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/324
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Platelet contractile force (PCF) is used as a surrogate marker of thrombin generation. PCF generation occurs concomitant with the burst of prothrombin fragment F 1+2 release. The time between assay start and PCF onset is identified as the thrombin generation time (TGT), and is used in assessing risk of bleeding, in diagnosing various disorders, and in monitoring the effects of pharmaceutical and other treatments. TGT is prolonged in clotting factor deficiencies and in the presence of direct and indirect thrombin inhibitors. TGT shortens to normal with clotting factor replacement and shortens with administration of rVIIa. TGT is short in thrombophilic states such as coronary artery disease, diabetes and thromboangiitis obliterans and prolongs toward normal with oral and intravenous anticoagulants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.